[1] Gnudi L,Coward R,Long D.Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms[J].Trends Endocrinol Metabol Tem,2016, 27(11):820-830.
[2] Bhattacharjee N,Barma S,Konwar N,et al. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update[J].European J Pharmacol,2016, 791:8-24.
[3] Cooke JN,Bostrom MA,Hicks PJ,et al. Polymorphisms in MYH9 are associated with diabetic nephropathy in European Americans[J].Nephrol Dial Transplant,2016, 27(4):1505-1511.
[4] Xiu ZM,Wang LP,Fu J,et al. 1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy[J].Biol Med Chem Letters,2017, 27(18).
[5] 杨秀颖, 张莉, 陈熙,等. 2型糖尿病周围神经病变机制研究进展[J].中国药理学通报, 2016, 32(05):598-602.
[6] 李平静, 李雷, 杨荣礼. 晚期糖基化终产物受体、可溶性晚期糖基化终产物受体与2型糖尿病心血管并发症的关系[J].医学综述, 2015(15):2783-2786.
[7] 刘文瑞, 廖琳, 路建饶. 糖尿病肾病的治疗进展[J].中国综合临床, 2017, 39(6):547-551.
[8] 叶皓, 阚启明, 匡亚飞,等.拉辛司克糖尿病肾病保护作用的分子机制[J].沈阳药科大学学报, 2016,33(7):560-564.
[9] 朱开梅, 唐丽霞, 赵文鹏,等.槲皮素脂质体对糖尿病肾病氧化应激和TGF-β1/Smad7通路的影响[J].安徽医科大学学报, 2017, 52(3):319-323. |
2020, Vol. 37 
